The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects and in Patients With Ischemic Heart Disease
Coronary Disease
About this trial
This is an interventional prevention trial for Coronary Disease focused on measuring coronary disease, atherosclerosis, endothelial function, caffeine, cerebrovascular disease, prevention
Eligibility Criteria
Inclusion Criteria:
- Patients with documented ischemic heart disease
- Healthy subjects who are not heavy regular coffee drinkers
Exclusion Criteria:
- Patients with unstable angina pectoris
- Patients with acute or chronic heart failure
- Patients with cardiac arrhythmia
Sites / Locations
- Heart Institute, Chaim Sheba Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
CAD patients
Placebo
Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.